Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.

Hiroki Kawashima; Akihiro Itoh; Eizaburo Ohno; Masanao Nakamura; Ryoji Miyahara; Naoki Ohmiya; Kazuo Hara; Akira Kanamori; Terutomo Itoh; Tomoyuki Taki

doi:10.1007/s00280-010-1531-6

Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.

Identifier:nobleid.org/w1/20260515/1B66FD8B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1B66FD8B.svg?ark=w1%2F20260515%2F1B66FD8B)](https://nobleid.org/work/w1/20260515/1B66FD8B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.

Identifier:nobleid.org/w1/20260515/1B66FD8B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/1B66FD8B.svg?ark=w1%2F20260515%2F1B66FD8B)](https://nobleid.org/work/w1/20260515/1B66FD8B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work